Effect of AC2993 with or without Immunosuppression on Beta Cell Function in Patients with Type 1 Diabetes
A team of diabetes doctors at the National Institutes of Health in Bethesda is looking for patients who are interested in being included in an exiting, new clinical trial. The goal is to find out whether insulin production can be improved in patients with long-standing type 1 diabetes (T1DM) with the help of a medicine called exendin-4 (or AC2993).
To be eligible, patients must be 18 to 60 years old, have T1DM for at least 5 years and must be willing and able to follow an intensive insulin regimen, have at least 0.5 ng/ml circulating C-peptide following an arginine bolus, and must be willing to travel to the NIH for a one- to three-day visit several times (travel expenses paid by the NIH except for the first screening visit) over an 18 month period. Half of the patients will be assigned (by chance) to take immunosuppressive drugs in addition to the study medicine exendin-4. We exclude patients with renal insufficiency, or other health problems that might place them at heightened risk were they to participate.
Individuals with interest should call our NIH patient recruitment office at 1-800-411-1222 or check out our website www.clinicaltrials.gov (then type in: exendin or type 1 diabetes).
[ Back to Studies Page ]
|Return to the Top of This Page|
Last Updated: (none)
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.